Archives: Agenda

FIRESIDE CHAT Risks & Controversies of AI in Clinical Trials

  • Automation bias in practice: Real-world cases show dosing errors occurring when clinicians rely on AI outputs without independent verification.
  • Human oversight failures: Over-reliance on AI, combined with missed pharmacist checks, can directly compromise patient safety.
  • Cognitive deskilling risk: Persistent dependence on AI may erode critical thinking, clinical judgement, and professional expertise over time.
  • Long-term human impact: Growing concern that excessive cognitive offloading to AI could contribute to reduced mental resilience and potential long-term cognitive health risks, highlighting the need for balanced human – AI interaction.

Adaptive Oncology Trials: Improving Access and the Patient Perspective

This session explores how adaptive trial designs are changing oncology research, enabling greater flexibility in trial arms and broader use of therapies across indications. We will discuss what this means for patient access and why embedding patient perspectives early is critical to successful study design and delivery.

ROUNDTABLE DISCUSSIONS

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table lead/host and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

ROUNDTABLE 1: Sponsor–CRO Relationships

Building Strong Sponsor – CRO Partnerships for Efficient Trial Delivery

 

ROUNDTABLE 2:  Taking the Wheel: Gaining Control of Your eTMF During Active Trials

Jane Silverwood, Clinical Documental Management Specialist, Owkin

 

ROUNDTABLE 3: Patient Centricity, Engagement & Retention

Putting Patients First: Strategies to Recruit, Engage and Retain Participants

 

ROUNDTABLE 4:   Developing medicines from analysis of real-world data

Myles Dakin, Chairman & Founder, Hypo-Stream

 

ROUNDTABLE 5: AI in Clinical Trials: Who Owns the Risk When Development is Outsourced?
Surbhi Gupta, Advisor to National AI team, NHS England
ROUNDTABLE 6: Can FAST-EU realistically accelerate multinational trial start-up, or will operational reality slow it down?

Victoria Toms, Executive Director, IAOCR